Highlights TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
7.73 ^USD	-0.90%		-9.70%	+32.59%

05-09	Tscan Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Tcr-T Therapy for the Treatment of Solid Tumors	CI
04-19	TScan Therapeutics Closes $150.1 Million Securities Offering	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tscan Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Tcr-T Therapy for the Treatment of Solid Tumors	05-09	CI
TScan Therapeutics Closes $150.1 Million Securities Offering	04-19	MT
TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants	04-17	MT
TScan Therapeutics Launches $125 Million Securities Offering; Shares Rise After Hours	04-16	MT
TScan Therapeutics, Inc. Provides Clinical Pipeline Update and Highlights Near-Term Priorities	04-16	CI
TScan Therapeutics Files $300 Million Mixed-Securities Shelf	03-06	MT
TScan Therapeutics Q4 Net Loss Narrows, Revenue Increases	03-06	MT
TScan Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-06	CI
Tscan Therapeutics, Inc. Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 At the 65Th American Society of Hematology Annual Meeting and Exposition	12-09	CI
TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
TScan Therapeutics Says Investigational New Drug Application for Solid Tumor Treatment Received US FDA Clearance	06/06/23	MT
TScan Therapeutics, Inc. Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting	17/05/23	CI
TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Amgen, TScan Therapeutics Partner to Identify Therapeutic Targets for Crohn's Disease Treatment	09/05/23	MT
Amgen and TScan Therapeutics Announces Collaboration to Identify Novel Targets in Crohn’s Disease	09/05/23	CI
TScan Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies	14/03/23	CI
TSCAN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	08/03/23	AQ
TScan Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	08/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Highlights

Filters